Mar 30, 2025 · PLAU (Plasminogen Activator, Urokinase) is a Protein Coding gene. Diseases associated with PLAU include Quebec Platelet Disorder and Alzheimer Disease, Familial, 1. Among its related pathways are ncRNAs involved in Wnt signaling in hepatocellular carcinoma and Innate Immune System.

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. [5] .

PLAU is a promising new candidate gene for late-onset Alzheimer's disease, with allele C (P141) being a recessive risk allele or allele T (L141) conferring protection. u-PA down-regulation by RNAi technology decreases the invasive capability of hepatocellular carcinoma cells

Jan 4, 2025 · Title: PLAU contributes to the development of cholangiocarcinoma via activating NF-κB signaling pathway. Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCalpha-p38 MAPK pathway-mediated progression of …

Jan 4, 2025 · Clinical resource with information about PLAU, Alzheimer disease type 1, Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease., Quebec platelet disorder, and available tests.

Elevated PLAU correlates with increased aggressive phenotypes, stromal score, and immune suppression in PDAC. PLAU upregulation is also closely associated with the basal subtype type of PDAC; patients with this subtype are at high risk of mortality from the disease and may benefit from therapeutic targeting of PLAU.

Urinary plasminogen activator (uPA, PLAU; EC 3.4.21.73) converts plasminogen (173350) to plasmin. Urokinase has a molecular mass of about 54 kD and is composed of 2 disulfide-linked chains, A and B, of molecular masses 18 kD and 33 kD, respectively.

Feb 11, 2010 · Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder linked to a region on chromosome 10 that includes PLAU, the urokinase plasminogen activator gene. QPD increases urokinase plasminogen activator mRNA levels, particularly during megakaryocyte differentiation, without altering expression of flanking genes.

Aug 28, 2023 · PLAU is a protease that converts plasminogen to plasmin. It appears to affect murine ageing: its overexpression in the brain diminishes food consumption and extends longevity probably through a mechanism similar to caloric restriction [13].

The urokinase-type plasminogen activator(PLAU) and its receptor PLAUR participate in a series of cell physiological activities on the extracellular surface. Abnormal expression of PLAU and PLAUR is associated with tumorigenesis.